Nha\u0302n kh\u00e2\u0309u ho\u0323c \u0111u\u031b\u01a1\u0323c ba\u0301o ca\u0301o trong Tab I. Kho\u0302ng ti\u0300m th\u00e2\u0301y s\u01b0\u0323 kha\u0301c bi\u1eb9\u0302t gi\u01b0\u0303a hai nho\u0301m.
\nHi\u1eb9\u0302u qua\u0309: \u0110i\u00ea\u0300u tri\u0323 v\u01a1\u0301i lipofilm la\u0300m gia\u0309m \u0111a\u0301ng k\u00ea\u0309 \u0111i\u00ea\u0309m s\u00f4\u0301 tri\u1eb9\u0302u ch\u01b0\u0301ng toa\u0300n c\u00e2\u0300u cu\u0303ng nhu\u031b ca\u0301c tri\u1eb9\u0302u ch\u01b0\u0301ng chu\u0309 quan v\u00ea\u0300 m\u1ea1\u0306t th\u00f4\u0301ng ke\u0302 (-69%) so v\u01a1\u0301i \u0111u\u031b\u01a1\u0300ng co\u031b s\u01a1\u0309, ngoa\u0323i tr\u01b0\u0300 ch\u01b0\u0301ng s\u01a1\u0323 a\u0301nh sa\u0301ng (Tab II). Vi\u1eb9\u0302c gia\u0309m \u0111i\u00ea\u0309m tri\u1eb9\u0302u ch\u01b0\u0301ng toa\u0300n c\u00e2\u0300u phu\u0323 thu\u1ecd\u0302c va\u0300o th\u01a1\u0300i gian (Fig 1).<\/p>\n

Tab l: Nha\u0302n kh\u00e2\u0309u ho\u0323c cu\u0309a \u0111\u00f4\u0301i tu\u031b\u01a1\u0323ng nghie\u0302n c\u01b0\u0301u<\/p>\n<\/div>\n<\/div>\n\n\n\n\n\n<\/colgroup>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

<\/td>\n \n
\n
\n
LIPOFILM<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
0 2% Sodium hyaluronate<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
P<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
\n
\n
Gi\u01a1\u0301i: Nam (N,%)<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
1 (89%)<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
1 (90%)<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
NS O<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
\n
\n
N\u01b0\u0303 (N,%)<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
8 (11%)<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
9 (10%)<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
\n
\n
Tu\u00f4\u0309i (Mean\u00b1SD)<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
53,1 \u00b1 13,9<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
60,8 \u00b1 13,8<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
NS (*)<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
\n
\n
Schirmer\u2019s test: mm (Mean\u00b1SD)<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
4,1 \u00b1 1,8<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
4,4 \u00b1 1,3<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
NS (*)<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
\n
\n
S\u01a1\u0323 a\u0301nh sa\u0301ng: score (Mean\u00b1SD)<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
1,1 \u00b1 0,8<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
1,2 0,9<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
NS (*)<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
\n
\n
No\u0301ng ra\u0301t\/\u0111au: score (Mean\u00b1SD)<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
1,9 \u00b1 0,6<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
2,0 \u00b1 0,8<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
NS (*)<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
\n
\n
Nhi\u0300n m\u01a1\u0300: score (MeaniSD)<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
1,2 \u00b1 1,2<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
1,0 \u00b1 0,8<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
NS (*)<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
\n
\n
Ca\u0309m gia\u0301c co\u0301 di\u0323 v\u1ea1\u0302t: score (Mean\u00b1SD)<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
2.1 \u00b1 0,3<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
2,3 \u00b1 0,7<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
NS (*)<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
\n
\n
Sung huy\u00ea\u0301t k\u00ea\u0301t ma\u0323c: VAS (MeaniSD)<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
37.4 \u00b1 17,5<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
48,5 \u00b1 22,3<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
NS (*)<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
\n
\n
Phu\u0300 n\u00ea\u0300 k\u00ea\u0301t ma\u0323c: VAS (Mean\u00b1SD)<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
15,4 \u00b1 12,2<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
14,2 \u00b1 13,5<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
NS (*)<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
\n
\n
Phu\u0300 mi\u0301: VAS ((Mean\u00b1SD)<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
19,1 \u00b1 21,3<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
19,5 \u00b1 25,8<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
NS (*)<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
\n
\n
Nhu\u1ecd\u0302m fluorescein: score (Mean\u00b1SD)<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
1,4\u00b1 \u00b1 0,5<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
1,8 \u00b1 0,8<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
NS (*)<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
\n
\n
BUT : sec (MeartfcSD)<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
4,6 \u00b1 1,3<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
5,1 \u00b1 1,4<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
NS (*)<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n
\n
\u00b0 Fisher\u2019s test; * Mann-Whitney\u2019s test; NS = kho\u0302ng co\u0301 y\u0301 nghi\u0303a th\u00f4\u0301ng ke\u0302<\/p>\n
Ngoa\u0300i ra ca\u0301c d\u00e2\u0301u hi\u1eb9\u0302u kha\u0301ch quan \u0111u\u031b\u01a1\u0323c ca\u0309i thi\u1eb9\u0302n \u0111a\u0301ng k\u00ea\u0309 khi \u0111i\u00ea\u0300u tri\u0323 v\u01a1\u0301i Lipofilm. Tre\u0302n th\u01b0\u0323c t\u00ea\u0301, vi\u1eb9\u0302c \u0111i\u00ea\u0300u tri\u0323 la\u0300m gia\u0309m \u0111a\u0301ng k\u00ea\u0309 \u0111i\u00ea\u0309m s\u00f4\u0301 cu\u0303ng nhu\u031b cu\u0309a t\u00e2\u0301t ca\u0309 ca\u0301c d\u00e2\u0301u hi\u1eb9\u0302u chu\u0309 quan \u0111u\u031b\u01a1\u0323c \u0111a\u0301nh gia\u0301 v\u00ea\u0300 m\u1ea1\u0306t th\u00f4\u0301ng ke\u0302 (-90%) so v\u01a1\u0301i \u0111u\u031b\u01a1\u0300ng co\u031b s\u01a1\u0309, loa\u0323i tr\u01b0\u0300 phu\u0300 mi\u0301 (Tab II). Ngoa\u0300i ra, vi\u1eb9\u0302c gia\u0309m \u0111i\u00ea\u0309m s\u00f4\u0301 cu\u0303ng phu\u0323 thu\u1ecd\u0302c va\u0300o th\u01a1\u0300i gian (Fig 2). K\u00ea\u0301t qua\u0309 tu\u031bo\u031bng t\u01b0\u0323 cu\u0303ng thu \u0111u\u031b\u01a1\u0323c \u01a1\u0309 nho\u0301m \u0111i\u00ea\u0300u tri\u0323 Natri Hyaluronate 0,2%, nhu\u031bng \u0111i\u00ea\u0300u tri\u0323 v\u01a1\u0301i Lipofilm cho k\u00ea\u0301t qua\u0309 t\u00f4\u0301t ho\u031bn \u0111a\u0301ng k\u00ea\u0309. Trong th\u01b0\u0323c t\u00ea\u0301 lipofilm cho th\u00e2\u0301y k\u00ea\u0301t qua\u0309 t\u00f4\u0301t ho\u031bn ca\u0309 v\u00ea\u0300 m\u01b0\u0301c \u0111\u1ecd\u0302 a\u0309nh hu\u031b\u01a1\u0309ng va\u0300 s\u00f4\u0301 lu\u031b\u01a1\u0323ng tham s\u00f4\u0301 kha\u0301c nhau v\u00ea\u0300 m\u1ea1\u0306t th\u00f4\u0301ng ke\u0302 so v\u01a1\u0301i \u0111u\u031b\u01a1\u0300ng co\u031b s\u01a1\u0309 (Fig 1, 2 va\u0300 Tab. II).<\/p>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n
Tab II: To\u0301m t\u0103\u0301t k\u00ea\u0301t qua\u0309<\/p>\n<\/div>\n<\/div>\n\n\n\n\n\n<\/colgroup>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n
\n
\n
LIPOFILM<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
0.2% Sodium hyalurcnate<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
\n
\n
Bi\u00ea\u0301n change<\/p>\n<\/div>\n<\/div>\n
\n
\n
\u20191LM<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
P*<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
change<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
P*<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
\n
\n
No\u0301ng ra\u0301t\/\u0111au -71%<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
P<0.05<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
-55%<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
P<0.05<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
\n
\n
S\u01a1\u0323 a\u0301nh sa\u0301ng -30%<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
NS<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
-50%<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
NS<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
\n
\n
Nhi\u0300n m\u01a1\u0300 -100%<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
P<0.05<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
-60%<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
NS<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
\n
\n
Ca\u0309m gia\u0301c co\u0301 di\u0323 v\u1ea1\u0302t -74%<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
P<0.01<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
-48%<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
P<0.01<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
\n
\n
Toa\u0300n b\u1ecd\u0302 tri\u1eb9\u0302u ch\u01b0\u0301ng -69%<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
P<0.01<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
-52%<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
P<0.05<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
\n
\n
Sung huy\u00ea\u0301t k\u00ea\u0301t ma\u0323c -85%<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
P<0.01<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
-51%<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
P<0.05<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
\n
\n
Phu\u0300 n\u00ea\u0300 k\u00ea\u0301t ma\u0323c -94%<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
P<0.05<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
-47%<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
NS<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
\n
\n
Phu\u0300 n\u00ea\u0300 mi\u0301 m\u0103\u0301t -97%<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
NS<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
-54%<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
NS<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
\n
\n
D\u00e2\u0301u hi\u1eb9\u0302u -90%<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
P<0.01<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
-51%<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
NS<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
\n
\n
Nhu\u1ecd\u0302m fluorescein -85%<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
P<0.01<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
-61%<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
P<0 05<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n
\n
\n
\n
BUT 13%<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
NS<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
12%<\/p>\n<\/div>\n<\/div>\n<\/td>\n
\n
\n
\n
NS<\/p>\n<\/div>\n<\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n
\n
* Wilcoxon\u2019s Test; NS = kho\u0302ng co\u0301 y\u0301 nghi\u0303a th\u00f4\u0301ng ke\u0302<\/p>\n
$\"PHOSPHOLIPID$ <\/p>\n
Fig 1: Ca\u0301c tri\u1eb9\u0302u ch\u01b0\u0301ng chu\u0309 quan (ch\u01b0\u0301ng s\u01a1\u0323 a\u0301nh sa\u0301ng; no\u0301ng ra\u0301t \/ \u0111au; m\u01a1\u0300 m\u0103\u0301t va\u0300 ca\u0309m gia\u0301c co\u0301 di\u0323 v\u1ea1\u0302t trong m\u0103\u0301t) thay \u0111\u00f4\u0309i trong su\u00f4\u0301t nghie\u0302n c\u01b0\u0301u. Ca\u0301c tri\u1eb9\u0302u ch\u01b0\u0301ng \u0111u\u031b\u01a1\u0323c thu th\u1ea1\u0302p b\u0103\u0300ng ca\u0301c thang \u0111o ba\u0301n \u0111i\u0323nh lu\u031b\u01a1\u0323ng va\u0300 \u0111u\u031b\u01a1\u0323c bi\u00ea\u0309u thi\u0323 b\u0103\u0300ng t\u00f4\u0309ng \u0111i\u00ea\u0309m. Ca\u0309i thi\u1eb9\u0302n co\u0301 y\u0301 nghi\u0303a th\u00f4\u0301ng ke\u0302 \u0111a\u0303 \u0111u\u031b\u01a1\u0323c ba\u0301o ca\u0301o \u01a1\u0309 ca\u0309 hai nho\u0301m (tu\u031bo\u031bng \u01b0\u0301ng P < 0,01 \u01a1\u0309 nho\u0301m \u0111u\u031b\u01a1\u0323c \u0111i\u00ea\u0300u tri\u0323 Lipofilm va\u0300 P < 0,05 \u01a1\u0309 nho\u0301m \u0111\u00f4\u0301i ch\u01b0\u0301ng). Tuy nhie\u0302n, k\u00ea\u0301t qua\u0309 t\u00f4\u0301t ho\u031bn \u0111a\u0303 \u0111u\u031b\u01a1\u0323c quan sa\u0301t th\u00e2\u0301y \u01a1\u0309 nh\u01b0\u0303ng b\u1eb9\u0302nh nha\u0302n \u0111u\u031b\u01a1\u0323c \u0111i\u00ea\u0300u tri\u0323 b\u0103\u0300ng Lipofilm.<\/p>\n
$\"PHOSPHOLIPID$ <\/p>\n
Fig 2: D\u00e2\u0301u hi\u1eb9\u0302u kha\u0301ch quan (sung huy\u00ea\u0301t k\u00ea\u0301t ma\u0323c; phu\u0300 k\u00ea\u0301t ma\u0323c va\u0300 phu\u0300 mi\u0301) thay \u0111\u00f4\u0309i trong su\u00f4\u0301t nghie\u0302n c\u01b0\u0301u. Ca\u0301c d\u00e2\u0301u hi\u1eb9\u0302u \u0111u\u031b\u01a1\u0323c thu th\u1ea1\u0302p b\u0103\u0300ng phu\u031bo\u031bng pha\u0301p cu\u0309a Visual Analogic Scales va\u0300 \u0111u\u031b\u01a1\u0323c bi\u00ea\u0309u thi\u0323 b\u0103\u0300ng t\u00f4\u0309ng s\u00f4\u0301 \u0111i\u00ea\u0309m ti\u0301nh b\u0103\u0300ng mm. K\u00ea\u0301t qua\u0309 gia\u0309m \u0111a\u0301ng k\u00ea\u0309 ca\u0301c d\u00e2\u0301u hi\u1eb9\u0302u \u0111a\u0303 \u0111u\u031b\u01a1\u0323c ba\u0301o ca\u0301o trong nho\u0301m \u0111u\u031b\u01a1\u0323c \u0111i\u00ea\u0300u tri\u0323 Lipofilm (P < 0,01). Nh\u01b0\u0303ng thay \u0111\u00f4\u0309i trong nho\u0301m ki\u00ea\u0309m soa\u0301t kho\u0302ng \u0111a\u0323t \u0111u\u031b\u01a1\u0323c y\u0301 nghi\u0303a th\u00f4\u0301ng ke\u0302.<\/p>\n
Lie\u0302n quan \u0111\u00ea\u0301n ca\u0301c d\u00e2\u0301u hi\u1eb9\u0302u cu\u0323 th\u00ea\u0309, trong nho\u0301m \u0111i\u00ea\u0300u tri\u0323 Natri Hyaluronate 0,2%, chi\u0309 co\u0301 s\u01b0\u0323 gia\u0309m ta\u0306ng k\u00ea\u0301t ma\u0323c la\u0300 co\u0301 y\u0301 nghi\u0303a th\u00f4\u0301ng ke\u0302 (Tab II) va\u0300 \u0111\u00f4\u0301i v\u01a1\u0301i ca\u0309 vi\u1eb9\u0302c la\u0300m gia\u0309m tri\u1eb9\u0302u ch\u01b0\u0301ng (Fig 2) va\u0300 d\u00e2\u0301u hi\u1eb9\u0302u (Fig 2) \u0111\u00ea\u0300u cho th\u00e2\u0301y hi\u1eb9\u0302u qua\u0309 t\u00f4\u0301t ho\u031bn \u01a1\u0309 nho\u0301m \u0111u\u031b\u01a1\u0323c \u0111i\u00ea\u0300u tri\u0323 v\u01a1\u0301i Lipofilm. Ca\u0309 Lipofilm va\u0300 0,2% Natri Hyaluronate \u0111\u00ea\u0300u \u0111em la\u0323i s\u01b0\u0323 gia ta\u0306ng kho\u0302ng \u0111a\u0301ng k\u00ea\u0309 BUT (Tab. II). Lie\u0302n quan \u0111\u00ea\u0301n Fluorescein nhu\u1ecd\u0302m tre\u0302n b\u00ea\u0300 m\u1ea1\u0306t gia\u0301c ma\u0323c \u0111\u00ea\u0300u \u0111em la\u0323i k\u00ea\u0301t qua\u0309 co\u0301 y\u0301 nghi\u0303a th\u00f4\u0301ng ke\u0302 \u01a1\u0309 ca\u0309 hai nho\u0301m, tuy nhie\u0302n s\u01b0\u0323 gia\u0309m nhi\u00ea\u0300u ho\u031bn \u01a1\u0309 nho\u0301m \u0111u\u031b\u01a1\u0323c \u0111i\u00ea\u0300u tri\u0323 Lipofilm (Tab.II).<\/p>\n
Kha\u0309 na\u0306ng dung na\u0323p: Kha\u0309 na\u0306ng dung na\u0323p ta\u0323i ch\u00f4\u0303 va\u0300 toa\u0300n tha\u0302n \u0111\u00ea\u0300u t\u00f4\u0301t. Kho\u0302ng co\u0301 s\u01b0\u0323 kha\u0301c bi\u1eb9\u0302t na\u0300o \u0111u\u031b\u01a1\u0323c quan sa\u0301t gi\u01b0\u0303a hai phu\u031bo\u031bng pha\u0301p \u0111i\u00ea\u0300u tri\u0323. Kho\u0302ng co\u0301 ta\u0301c du\u0323ng phu\u0323 na\u0300o \u0111u\u031b\u01a1\u0323c ba\u0301o ca\u0301o.<\/p>\n
THA\u0309O LU\u1ea0\u0302N<\/h2>\n
Lipofilm du\u031b\u01a1\u0300ng nhu\u031b co\u0301 hi\u1eb9\u0302u qua\u0309 trong vi\u1eb9\u0302c gia\u0309m ca\u0301c d\u00e2\u0301u hi\u1eb9\u0302u va\u0300 tri\u1eb9\u0302u ch\u01b0\u0301ng \u01a1\u0309 b\u1eb9\u0302nh nha\u0302n bi\u0323 kho\u0302 m\u0103\u0301t. Ta\u0301c du\u0323ng na\u0300y \u0111a\u0303 \u0111u\u031b\u01a1\u0323c ti\u0300m th\u00e2\u0301y ta\u0306ng le\u0302n trong su\u00f4\u0301t qua\u0301 tri\u0300nh \u0111i\u00ea\u0300u tri\u0323, cho th\u00e2\u0301y hi\u1eb9\u0302u qua\u0309 cu\u0309a Lipofilm trong vi\u1eb9\u0302c gia\u0309i quy\u00ea\u0301t tri\u1eb9\u0302u ch\u01b0\u0301ng cu\u0309a ti\u0300nh tra\u0323ng b\u1eb9\u0302nh ly\u0301 \u0111u\u031b\u01a1\u0323c coi la\u0300 ma\u0323n ti\u0301nh. Lipofilm du\u031b\u01a1\u0300ng nhu\u031b co\u0301 hi\u1eb9\u0302u qua\u0309 ho\u031bn trong vi\u1eb9\u0302c gia\u0309m ca\u0309 ca\u0301c d\u00e2\u0301u hi\u1eb9\u0302u va\u0300 tri\u1eb9\u0302u ch\u01b0\u0301ng so v\u01a1\u0301i thu\u00f4\u0301c nho\u0309 m\u0103\u0301t co\u0301 ch\u01b0\u0301a 0,2% natri hyaluronate.<\/p>\n
L\u01a1\u0301p lipid m\u0103\u0301t la\u0300 m\u1ecd\u0302t l\u01a1\u0301p ma\u0300ng lipid r\u00e2\u0301t mo\u0309ng, \u0111u\u031b\u01a1\u0323c sinh ra b\u01a1\u0309i tuy\u00ea\u0301n Meibomian, v\u01a1\u0301i ch\u01b0\u0301c na\u0306ng quan tro\u0323ng la\u0300 tri\u0300 hoa\u0303n s\u01b0\u0323 bay ho\u031bi nu\u031b\u01a1\u0301c m\u0103\u0301t do \u0111o\u0301 duy tri\u0300 s\u01b0\u0323 \u00f4\u0309n \u0111i\u0323nh va\u0300 ti\u0301nh th\u00e2\u0309m th\u00e2\u0301u cu\u0309a ma\u0300ng nu\u031b\u01a1\u0301c m\u0103\u0301t. S\u01b0\u0323 pha\u0301 v\u01a1\u0303 ma\u0300ng lipid co\u0301 lie\u0302n quan \u0111\u00ea\u0301n ca\u0301c b\u1eb9\u0302nh ly\u0301 tre\u0302n b\u00ea\u0300 m\u1ea1\u0306t m\u0103\u0301t kha\u0301c nhau, \u0111\u1ea1\u0306c bi\u1eb9\u0302t la\u0300 h\u1ecd\u0302i ch\u01b0\u0301ng kho\u0302 m\u0103\u0301t. Ngu\u031b\u01a1\u0300i ta tin r\u0103\u0300ng ph\u00e2\u0300n l\u01a1\u0301n (ho\u031bn 75%) b\u1eb9\u0302nh nha\u0302n kho\u0302 m\u0103\u0301t co\u0301 lie\u0302n quan \u0111\u00ea\u0301n t\u00f4\u0309n thu\u031bo\u031bng l\u01a1\u0301p lipid ma\u0300ng nu\u031b\u01a1\u0301c m\u0103\u0301t. Vi\u1eb9\u0302c phu\u0323c h\u00f4\u0300i l\u01a1\u0301p lipid ma\u0300ng nu\u031b\u01a1\u0301c m\u0103\u0301t thu\u031b\u01a1\u0300ng \u0111u\u031b\u01a1\u0323c xem la\u0300 m\u1ecd\u0302t nhi\u1eb9\u0302m vu\u0323 kho\u0301 kha\u0306n pha\u0309i hoa\u0300n tha\u0300nh. M\u1ecd\u0302t pha\u0301t hi\u1eb9\u0302n quan tro\u0323ng \u0111u\u031b\u01a1\u0323c ghi nh\u1ea1\u0302n nghie\u0302n c\u01b0\u0301u na\u0300y la\u0300 \u01a1\u0309 nh\u01b0\u0303ng b\u1eb9\u0302nh nha\u0302n \u0111u\u031b\u01a1\u0323c \u0111i\u00ea\u0300u tri\u0323 b\u0103\u0300ng Lipofilm \u0111a\u0303 gia\u0309m \u0111a\u0301ng k\u00ea\u0309 t\u00e2\u0300m nhi\u0300n m\u01a1\u0300 so v\u01a1\u0301i \u0111u\u031b\u01a1\u0300ng co\u031b s\u01a1\u0309 \u0111u\u031b\u01a1\u0323c ba\u0301o ca\u0301o ma\u0300 kho\u0302ng co\u0301 b\u00e2\u0301t ky\u0300 r\u00f4\u0301i loa\u0323n thi\u0323 gia\u0301c na\u0300o lie\u0302n quan \u0111\u00ea\u0301n vi\u1eb9\u0302c s\u01b0\u0309 du\u0323ng sa\u0309n ph\u00e2\u0309m. \u0110i\u00ea\u0300u na\u0300y ch\u01b0\u0301ng to\u0309 r\u0103\u0300ng Lipofilm la\u0300 h\u00f4\u0303n h\u01a1\u0323p ca\u0302n b\u0103\u0300ng lipid pha\u0302n c\u01b0\u0323c va\u0300 lipit kho\u0302ng pha\u0302n c\u01b0\u0323c, phu\u0300 h\u01a1\u0323p v\u00ea\u0300 m\u1ea1\u0306t sinh ly\u0301 trong nu\u031b\u01a1\u0301c m\u0103\u0301t t\u01b0\u0323 nhie\u0302n, co\u0301 th\u00ea\u0309 \u0111i\u00ea\u0300u chi\u0309nh s\u01b0\u0323 thay \u0111\u00f4\u0309i lipid ma\u0300 kho\u0302ng a\u0309nh hu\u031b\u01a1\u0309ng \u0111\u00ea\u0301n ch\u00e2\u0301t lu\u031b\u01a1\u0323ng quang ma\u0300ng nu\u031b\u01a1\u0301c m\u0103\u0301t. \u0110i\u00ea\u0300u tri\u0323 giai \u0111oa\u0323n \u0111\u00e2\u0300u cho ti\u0300nh tra\u0323ng kho\u0302 m\u0103\u0301t khi s\u01b0\u0309 du\u0323ng thu\u00f4\u0301c nho\u0309 m\u0103\u0301t tho\u0302ng thu\u031b\u01a1\u0300ng, \u0111a ph\u00e2\u0300n \u0111\u00ea\u0300u c\u00e2\u0300n cung c\u00e2\u0301p m\u1ecd\u0302t gia\u0309i pha\u0301p \u0111\u00ea\u0309 ha\u0323n ch\u00ea\u0301 vi\u1eb9\u0302c nhi\u0300n m\u01a1\u0300. Ngoa\u0300i ra, m\u1ecd\u0302t s\u00f4\u0301 sa\u0309n ph\u00e2\u0309m na\u0300y th\u1ea1\u0302m chi\u0301 co\u0301 th\u00ea\u0309 la\u0300m ta\u0306ng t\u00f4\u0301c \u0111\u1ecd\u0302 bay ho\u031bi nu\u031b\u01a1\u0301c m\u0103\u0301t. To\u0301m la\u0323i, k\u00ea\u0301t qua\u0309 hi\u1eb9\u0302n ta\u0323i chi\u0309 ra r\u0103\u0300ng vi\u1eb9\u0302c s\u01b0\u0309 du\u0323ng Lipofilm, m\u1ecd\u0302t loa\u0323i d\u00e2\u0300u trong vi nhu\u0303 tu\u031bo\u031bng co\u0301 ch\u01b0\u0301c na\u0306ng sinh ly\u0301 r\u00e2\u0301t g\u00e2\u0300n v\u01a1\u0301i l\u01a1\u0301p lipid nu\u031b\u01a1\u0301c m\u0103\u0301t, th\u00ea\u0309 hi\u1eb9\u0302n m\u1ecd\u0302t gia\u0309i pha\u0301p m\u01a1\u0301i trong \u0111i\u00ea\u0300u tri\u0323 kho\u0302 m\u0103\u0301t.<\/p>\n
TA\u0300I LI\u1eb8\u0302U THAM KHA\u0309O<\/h2>\n
1. 2. 3.
\nDATA ON FILE, TUBILUX PHARMA S.P.A.: Clinical Investigator\u2019s Brochure, version 1.0, November 2002.<\/p>\n
DATA ON FILE TUBILUX PHARMA S.P.A.: Pharmaceutical composition for the treatment of the eye. International Patent Application N\u00b0 PCT\/IL 98\/ 00012..
\nNORN MS: Desiccation of the precorneal film. I. Corneal wetting time. Acta Ophthalmol 47:865-880,1969.<\/p>\n<\/div>\n<\/div>\n<\/div>\n
Ta\u0301c gia\u0309:<\/h2>\n
P Aragona (I)3 M Rolando (2), S Bonini(3-, C Barozzi(4), R Falchetti(4,5), F De Gregorio(4,6). INSTI’priONS:<\/p>\n
(1) University of Messina, Italy; (2) Cli\u0301nica Oculi\u0301stica, University of Genoa, Italy; (3) Cli\u0301nica Oculi\u0301stica, \u201cCampus University, Rome, Italy (4)<\/p>\n
(5) CNR-INMM, Rome, Italy; Rep. Fisiopatologia Comeale, University, Rome,<\/p>\n
<\/p>\n","protected":false},"excerpt":{"rendered":"
\u0110A\u0301NH GIA\u0301 HI\u1eb8\u0302U QUA\u0309 VA\u0300 AN TOA\u0300N CU\u0309A PHOSPHOLIPID V\u01a0\u0301I C\u00c2\u0301U TRU\u0301C H\u1eb8\u0302 VI NHU\u0303 TU\u031bO\u031bNG (LIPOFILM) TRE\u0302N B\u1eb8\u0302NH NHA\u0302N BI\u0323 VIE\u0302M K\u00ca\u0301T \u2013 GIA\u0301C MA\u0323C KHO\u0302: M\u1ecc\u0302T TH\u01af\u0309 NGHI\u1eb8\u0302M LA\u0302M SA\u0300NG NG\u00c2\u0303U NHIE\u0302N, MU\u0300 \u0110O\u031bN \u0110\u1ea0\u0306T V\u00c2\u0301N \u0110\u00ca\u0300: Lipofilm la\u0300 m\u1ecd\u0302t vi nhu\u0303 tu\u031bo\u031bng. V\u00ea\u0300 m\u1ea1\u0306t nhi\u1eb9\u0302t \u0111\u1ecd\u0302ng, s\u01b0\u0323 pha\u0302n ta\u0301n d\u00e2\u0300u cu\u0309a no\u0301 […]\n","protected":false},"author":1,"featured_media":9970,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9966","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-y-te-suc-khoe"],"acf":[],"_links":{"self":[{"href":"https:\/\/vnras.com\/drug\/wp-json\/wp\/v2\/posts\/9966","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vnras.com\/drug\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vnras.com\/drug\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vnras.com\/drug\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/vnras.com\/drug\/wp-json\/wp\/v2\/comments?post=9966"}],"version-history":[{"count":0,"href":"https:\/\/vnras.com\/drug\/wp-json\/wp\/v2\/posts\/9966\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vnras.com\/drug\/wp-json\/wp\/v2\/media\/9970"}],"wp:attachment":[{"href":"https:\/\/vnras.com\/drug\/wp-json\/wp\/v2\/media?parent=9966"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vnras.com\/drug\/wp-json\/wp\/v2\/categories?post=9966"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vnras.com\/drug\/wp-json\/wp\/v2\/tags?post=9966"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}